At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 300 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Functional Impact of GLP-1 for Heart Failure Treatment
In Brief
A Phase 2 clinical trial evaluating Liraglutide and Placebo for Acute Heart Failure. Completed, enrolled 300 participants across 25 sites.
Detailed Summary
The primary objective is to test the hypothesis that, compared with placebo, therapy with Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge period will be associated with greater clinical stability at six months as assessed by a composite clinical endpoint.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Heart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionOct 2015
TodayJul 2026
First PostedFeb 28, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.3 years ago
Interventions
Liraglutidedrug
Active Drug
Placebodrug
Placebo